GlassScriptPhysician profile
Isabel Casimiro
NPI 1942615596
$2,379.40
in general payments reported to CMS, 2019-2025
15 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.00 · 2022: $127 · 2023: $1,080 · 2024: $440 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.40 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $733.91 | 2022-2023 | Tepezza |
| Amgen INC. | $476.00 | 2022-2025 | Tepezza, Repatha |
| Kyowa Kirin, INC. | $178.53 | 2023-2024 | Crysvita |
| Esperion Therapeutics, INC. | $175.72 | 2025 | Nexletol |
| Mannkind Corporation | $149.09 | 2023-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $137.12 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $131.06 | 2019-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $113.09 | 2024 | Korlym |
| Lilly USA, LLC | $79.71 | 2023 | Mounjaro, Trulicity, Taltz |
| Madrigal Pharmaceuticals | $79.47 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $59.93 | 2024-2025 | Strensiq |
| Dexcom, INC. | $24.81 | 2022 | |
| Medtronic, INC. | $20.80 | 2023 | Inpen Smart Insulin Delivery System |
| Amryt Pharma Holdings LTD | $19.33 | 2023 | Mycapssa |
| Travere Therapeutics, INC. | $0.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Casimiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.